What baseline assessments and monitoring are required when initiating bupropion‑SR (bupropion sustained‑release) as augmentation to sertraline?

Baseline Assessments and Monitoring When Starting Bupropion as Augmentation

When initiating bupropion as augmentation to sertraline, patients require baseline blood pressure measurement, seizure risk assessment, and close monitoring for neuropsychiatric symptoms (especially suicidal ideation) beginning within 1-2 weeks of starting treatment. 1, 2

Critical Pre-Treatment Evaluations

Seizure Risk Assessment

Before prescribing bupropion, you must screen for contraindications that lower seizure threshold 2:

• History of seizures or seizure disorder (absolute contraindication)
• Eating disorders (anorexia nervosa or bulimia - absolute contraindication)
• CNS conditions: stroke, severe head injury, brain metastases, CNS tumor or infection
• Substance use patterns: current alcohol abuse, benzodiazepine use, or abrupt discontinuation of alcohol/sedatives
• Metabolic disorders: diabetes treated with insulin or oral hypoglycemics, hypoglycemia, hyponatremia, severe hepatic impairment
• Concurrent medications: other medications lowering seizure threshold (antipsychotics, tricyclics, theophylline, systemic corticosteroids)

The seizure risk with bupropion SR is approximately 0.1% at doses up to 300 mg/day, but increases nearly tenfold at higher doses 2.

Cardiovascular Baseline

Measure blood pressure before starting bupropion 2. The drug can cause hypertension, particularly when combined with other antidepressants. In clinical trials, 2% of patients developed hypertension requiring discontinuation 2. The risk is amplified when bupropion is combined with sertraline due to increased dopaminergic and noradrenergic activity.

Medication Interaction Review

Verify the patient is not taking MAOIs (contraindicated - must wait 14 days after MAOI discontinuation) 3, 2. Also check for:

• Tamoxifen (bupropion contraindicated)
• Opioid medications (naltrexone component in some formulations would interfere)
• Other medications metabolized by CYP2B6

Interestingly, sertraline may actually increase bupropion metabolism slightly through CYP2B6 induction 4, though this interaction appears clinically mild.

Ongoing Monitoring Schedule

Weeks 1-2: Intensive Neuropsychiatric Monitoring

This is the highest-risk period for suicidal ideation and behavioral changes 1, 5. The FDA mandates close monitoring during this window. Specifically assess for:

• Suicidal thoughts or behaviors
• Agitation, irritability, hostility
• Unusual behavioral changes
• Anxiety, panic attacks
• Insomnia
• Akathisia (psychomotor restlessness)
• Hypomania or mania

Both bupropion and sertraline carry black box warnings for increased suicidality in patients under age 24, though the absolute risk is low (1% vs 0.2% placebo, NNH = 143) 6, 1.

Weeks 2-8: Treatment Response Assessment

Evaluate therapeutic response and adverse effects regularly 1. If no adequate response by 6-8 weeks, modify treatment 1. The STAR*D trial data shows bupropion augmentation achieves approximately 54% response rates when added to SSRIs 7, 8.

Blood Pressure Monitoring

Check blood pressure periodically throughout treatment 2. In seasonal affective disorder trials, mean systolic BP increased 1.3 mmHg with bupropion (statistically significant, p=0.013), and 2% developed hypertension requiring discontinuation 2.

Serotonin Syndrome Vigilance

When combining bupropion with sertraline, monitor for serotonin syndrome symptoms 5:

• Mental status changes (agitation, confusion, delirium)
• Autonomic instability (tachycardia, labile BP, diaphoresis, hyperthermia)
• Neuromuscular symptoms (tremor, rigidity, hyperreflexia, myoclonus)
• GI symptoms (nausea, vomiting, diarrhea)

While serotonin syndrome is more common with MAOI combinations, the risk exists with any serotonergic drug combination 5.

Dosing Considerations for Safety

Start bupropion SR at 150 mg once daily for 3 days, then increase to 150 mg twice daily if tolerated 9, 10. Maximum dose is 300 mg/day for augmentation. Gradual titration minimizes seizure risk and allows early detection of adverse effects 2.

Common Pitfalls to Avoid

1. Don't skip the seizure history - this is the most serious risk with bupropion and is entirely preventable through proper screening
2. Don't assume prior SSRI tolerance predicts bupropion tolerance - the side effect profiles differ substantially
3. Don't wait months to assess response - if no improvement by 6-8 weeks, change strategy 1
4. Don't forget to counsel about insomnia - give the second dose before 3 PM to minimize sleep disruption 10

The evidence supporting bupropion augmentation comes primarily from the STAR*D trial 8 and open-label studies 7, showing superiority over buspirone augmentation across antidepressive effect, side effects, and quality of life domains.